Omeros (OMER) Q3 2026 Earnings Call Transcript
Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.
How this was made

The 30-second read
Why it matters
The transcript emphasizes accelerating account adoption, outpatient utilization via 340B, and a Medicare NTAP add-on effective Oct. 1, while also explaining GAAP losses driven by noncash marks on embedded derivatives in its 2029 convertible notes.
Market read
Traders get actionable commercialization and reimbursement datapoints (account growth, outpatient 340B participation, NTAP effective date) plus capital-structure actions (convertible note repurchases) that can shift near-term sentiment.
What to watch
340B reimbursement rule changes begin Jan. 1, 2027, so traders should monitor whether YARTEMLEA’s pass-through status and outpatient economics remain favorable beyond June 2029.
Background
Omeros’ Q3 2026 earnings call focuses on YARTEMLEA commercialization progress for TA-TMA, including field education expansion and reimbursement positioning.
Ticker impact
Omeros reports Q3 YARTEMLEA sales growth, expanding outpatient 340B use, and highlights Medicare NTAP reimbursement effective Oct. 1.
Likely upward bias as traders focus on accelerating adoption, reimbursement tailwinds (NTAP), and reduced convertible-note overhang.
The transcript provides multiple decision-relevant datapoints (sales growth, account growth, NTAP effective date, and share/convertible repurchases) but is not a fresh earnings print with new guidance beyond the call’s disclosed quarter results.
Market effects
Reimbursement mechanics (NTAP and 340B rule changes) can influence sentiment toward other transplant and specialty biotech commercialization models.
Primarily US-focused reimbursement and transplant-center adoption dynamics.
Limited direct global read-through; reimbursement policy is US-specific.
Counterpoint
GAAP results remain deeply loss-making due to noncash derivative remeasurement, so equity upside may be capped until operating profitability and cash burn trajectory improve.
Key entities
- companyOmeros
US-listed biotech (OMER) commercializing YARTEMLEA and managing convertible-note dilution/interest exposure.
- productYARTEMLEA
TA-TMA therapy whose sales growth and reimbursement advantages are central to the call.
- policy340B reimbursement
CMS rule changes effective Jan. 1, 2027, with transitional pass-through status affecting economics.
- reimbursementNTAP
Medicare technology add-on payment providing up to $287,000 additional reimbursement per eligible inpatient case.

